GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parmax Pharma Ltd (BOM:540359) » Definitions » Ending Cash Position

Parmax Pharma (BOM:540359) Ending Cash Position : ₹0.0 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Parmax Pharma Ending Cash Position?

Parmax Pharma's Ending Cash Position for the quarter that ended in Dec. 2024 was ₹0.0 Mil.

Parmax Pharma's annual Ending Cash Position declined from Mar. 2022 (₹10.5 Mil) to Mar. 2023 (₹4.1 Mil) and declined from Mar. 2023 (₹4.1 Mil) to Mar. 2024 (₹0.6 Mil).

Parmax Pharma Ending Cash Position Historical Data

The historical data trend for Parmax Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parmax Pharma Ending Cash Position Chart

Parmax Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.68 27.46 10.54 4.07 0.57

Parmax Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Parmax Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Parmax Pharma's Ending Cash Position for the fiscal year that ended in Mar. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=4.068+-3.496
=0.6

Parmax Pharma's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0.0

Parmax Pharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Parmax Pharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Parmax Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parmax Pharma Ltd (BOM:540359) » Definitions » Ending Cash Position
Comparable Companies
BOM:524768 NSE:SAROJA BOM:531210 BOM:531015 BOM:523620 BOM:531521 BOM:524752 BOM:524606 BOM:531762 BOM:524516 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Rajkot-Gondal National Highway No. 27, Plot No. 20, Survey No. 52, Taluka Kotda Sangani, Hadamtala, Rajkot, GJ, IND, 360 311
Website
https://www.parmaxpharma.com
Parmax Pharma Ltd is a pharmaceutical company. The company manufactures and sells Tablets, Capsules, Ointments, and injectables. Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Paliperidone, Lacosamide, 2-Acetyl Benzo(B) Thiophene, Camphor Sulfonyl Chloride, 3-Methoxy Thiophene, Silodosin API, and others.

Parmax Pharma Headlines

No Headlines